Category - Developments

Developments

Zenabis outperforms revised cannabis design capacity by 41% in August

Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...

September 18, 2019

Developments

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...

September 18, 2019

Developments

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...

September 18, 2019

Developments

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

OrthoSpin, a portfolio of company of The Trendlines Group (OTCQX:TRNLY; SGX:42T) received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The use of external...

September 18, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Developments

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...

September 17, 2019

Developments

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

Allena Pharmaceuticals (NASDAQ:ALNA) has completed enrollment in the first of two Phase 3 clinical trials of reloxaliase for the treatment of enteric hyperoxaluria. Enteric hyperoxaluria occurs when an underlying...

September 16, 2019

Developments

FDA AdCom votes to approve Aimmune’s PALFORZIA for peanut allergy

An advisory committee of the FDA voted to support the use of Aimmune Therapeutics’ (NASDAQ:AIMT) PALFORZIA in children and teens with peanut allergy. The committee voted seven-to-two that the efficacy data and eight-to...

September 16, 2019

Developments

Bellerophon gets FDA orphan drug designation for IPF therapy

Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the...

September 16, 2019

Developments

Verrica Pharma submits NDA for molluscum contagiosum drug

Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...

September 16, 2019

Category - Developments

Zenabis outperforms revised cannabis design capacity by 41% in August

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

Trendlines OrthoSpin receives FDA clearance for robotic orthopedic treatments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

Concert Pharma completes enrollment in second open label alopecia areata trial

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

FDA AdCom votes to approve Aimmune’s PALFORZIA for peanut allergy

Bellerophon gets FDA orphan drug designation for IPF therapy

Verrica Pharma submits NDA for molluscum contagiosum drug

General

More